ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering

Tuesday, June 9, 2026GlobalData HealthcareView original

Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control.

Read the full article on the original site.